glp 1 oral tablets FDA Approved: Orforglipron (Foundayo) — GLP-1 Drug • FDA approved for chronic weight management • Indicated for obesity and overweight with comorbidities • Oral, once-daily GLP-1 receptor agonist • First non-peptide A GLP-1 Pill May Help

A primary concern for menopausal GLP-1 users is the potential for accelerated bone thinning and muscle loss, which is why experts emphasize the necessity of a high protein intake and consistent strength training to mitigate these risks

GLP-1 receptors can be found throughout the body most importantly for our purposes, in the GI tract, pancreas, and brain

Modern GLP-1s like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have far more powerful effects

Both immediate-release exenatide (Byetta) and extended-release exenatide (Bydureon BCise) have established gastrointestinal side effect profiles, though they are less commonly prescribed today due to the availability of more convenient once-weekly alternatives

The effects of GLP-1 agonists on musculoskeletal health and orthopedic care